Trials / Completed
CompletedNCT06568952
Right Ventricular Function in Patients Taking Carfilzomib
Right Ventricular Function of Patients With Multiple Myeloma Treated With Carfilzomib
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 36 (actual)
- Sponsor
- Central Hospital, Nancy, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients treated for multiple myeloma in the second line with carfilzomib may develop pulmonary hypertension. This is well documented in the literature. However, there are no studies looking at right ventricular function in these patients, both before and during treatment.
Detailed description
Patients treated for multiple myeloma in the second line with carfilzomib may develop pulmonary hypertension. This is well documented in the literature. However, there are no studies looking at right ventricular function in these patients, both before and during treatment. Patients had a cardiac ultrasound scan prior to the introduction of carfilzomib and an ultrasound scan following the introduction of carfilzomib. We will look at the evolution of right ventricular function parameters in these patients.
Conditions
Timeline
- Start date
- 2024-04-30
- Primary completion
- 2024-06-30
- Completion
- 2024-07-30
- First posted
- 2024-08-23
- Last updated
- 2024-08-23
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06568952. Inclusion in this directory is not an endorsement.